In Pfizer-Seagen review, FTC has chance to set new pharma precedent

Pfizer’s planned $43 billion acquisition of Seagen will be a major test for the Federal Trade Commission since the monopoly-regulating agency revised its views of what constitutes anti-competitive behavior in the pharmaceutical industry.